Cancer Chemotherapy and Pharmacology

, Volume 20, Issue 3, pp 219–222

Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients

  • Garth Powis
  • Phillip Reece
  • David L. Ahmann
  • James N. Ingle
Original Articles Cyclophosphamide, Pharmacokinetics, Breast Cancer

Summary

Cyclophosphamide pharmacolinetics have been studied in 16 female patients with advanced breast cancer. The group included 7 patients who were >20%, ≤30% over ideal body weight and 5 patients who were >30% over ideal body weight. Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.31 (mean 36.11), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min). There was a significant positive correlation (r=0.624,P=0.010) between body weight and plasma elimination half-life, and a significant negative correlation between body weight and cyclophosphamide clearance when normalized to body surface area (r=0.578,P=0.019) or normalized to ideal body weight (r=0.531,P=0.0345). the apparent volume of distribution did not correlate with body weight. The results show that cyclophosphamide disposition is altered in patients with increased body weight.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • Garth Powis
    • 1
  • Phillip Reece
    • 2
  • David L. Ahmann
    • 2
  • James N. Ingle
    • 2
  1. 1.Department of PharmacologyMayo Clinic & FoundationRochesterUSA
  2. 2.Department of OncologyMayo Clinic & FoundationRochesterUSA
  3. 3.Department of Clinical PharmacologyQueen Elizabeth HospitalWoodvilleAustralia

Personalised recommendations